Applying the updated 2014 blood pressure (BP) guideline to the U.S. population suggests that nearly 6 million adults are no longer classified as needing hypertension medication, and that an estimated 13.5 million adults would now be considered as having achieved goal blood pressure, primarily older adults, according to a JAMA study released online to coincide with the 2014 American College of Cardiology Scientific Sessions.
Ann Marie Navar-Boggan, M.D., Ph.D., of Duke University Medical Center, Durham, N.C., and colleagues quantified the proportion of adults potentially affected by the updated 2014 recommendations, compared to the previous guideline, issued nearly 10 years ago (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [JNC 7]). The researchers used data from the National Health and Nutrition Examination Survey (NHANES) between 2005 and 2010 (n = 16,372), and evaluated hypertension control and treatment recommendations for U.S. adults. The new guideline proposed less restrictive BP targets for adults 60 years of age or older and for those with diabetes and chronic kidney disease.
Using Age to Distinguish Normal From Abnormal Blood Test Results Appears to Safely Exclude Lung Blood Clots in Older Patients
Chicago – Using a patient’s age to raise the threshold for an abnormal result of a blood test used to assess patients with a suspected pulmonary embolism (blood clot in lungs) appeared to be safe and led to fewer healthy patients with the diagnosis, according to a study in the March 19 issue of JAMA.
D-dimer is a breakdown product of a blood clot, and measuring D-dimer levels is one way doctors exclude a diagnosis of pulmonary embolism (PE). Several studies have shown that D-dimer levels increase with age. As a result, the proportion of healthy patients with abnormal test results (above 500 µg/L for most available commercial tests) increases with age, limiting the test’s clinical usefulness in older people, according to background information in the article.
Researchers have found that blood of youngsters can rejuvenate the heart of the old ones – at least in mice.
Previously, researchers found that the blood from the young mice could rejuvenate the brain of the older mice. (Nature, doi:10.1038/nature10357).
In the new study, researchers worked on two mice; one was 2-month-old and the other was 23-month-old having cardiac hypertrophy – a condition in which the heart muscle thickens leading to heart failure. Researchers surgically joined the circulatory system of the two mice that caused the blood to flow around each other’s bodies.
Researchers found that the heart of the older mouse reverted back to almost the same size as that of the younger animal and the heart of the younger animal remained unaffected even after circulating the blood from the older mice. Read more…
This research has been published online in the Journal of the American Medical Association.
Researchers, in this study, worked on a corn-based hydroxyethyl starch solution, a commonly used blood volume expander, and compared it with other products. Researchers worked on 38 clinical trials involving 10,880 patients around the world and found that the chances of kidney failure and mortality were more in the patients, who received hydroxyethyl starch solutions.
“It’s used around the world in emergency rooms, intensive care units and surgical suites,” Zarychanski said in a short video produced by the university.
“Physicians like myself have often suspected the product may be associated with harm, but no study was adequately … designed to test this hypothesis.”
“We looked at all the studies conducted throughout the world to date on this product and we found clear evidence that in patients who received this product, compared to patients who received other resuscitation fluids, those patients have a greater chance of dying and having acute renal failure,” he added. Read more…
Diagnostic tool to determine down to 20 nm of individual particles in blood sample at an early stage
Researchers from Norway have developed the sensor that is capable of determining the individual particles in the blood sample and can help to detect cancer such as prostate and ovarian cancer in very early stages.
It is the world’s first sensor with such capability of determination developed by researchers from SINTEF, the largest independent research organization in Scandinavia, in collaboration with the researchers from Stanford University in the USA and the University of Oslo (UiO). This nano-particle sensor has been developed in MiNaLab in Oslo.